Last reviewed · How we verify
Abecma (idecabtagene vicleucel)
Abecma (generic name: idecabtagene vicleucel) is a drug developed by Bristol-Myers Squibb. It is currently FDA-approved.
At a glance
| Generic name | idecabtagene vicleucel |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| Annual revenue | 427 |
Approved indications
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Abecma CI brief — competitive landscape report
- Abecma updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI
Frequently asked questions about Abecma
What is Abecma?
Abecma (idecabtagene vicleucel) is a pharmaceutical drug developed by Bristol-Myers Squibb.
Who makes Abecma?
Abecma is developed and marketed by Bristol-Myers Squibb (see full Bristol-Myers Squibb pipeline at /company/bristol-myers-squibb).
What is the generic name of Abecma?
idecabtagene vicleucel is the generic (nonproprietary) name of Abecma.
What development phase is Abecma in?
Abecma is FDA-approved (marketed).
What is Abecma's annual revenue?
Abecma generated approximately $0.0B in annual revenue.
Related
- Manufacturer: Bristol-Myers Squibb — full pipeline
- Therapeutic area: All drugs in Oncology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing